Sudapyridine

DB18984InvestigationalSmall molecule

Sudapyridine is under investigation in clinical trial NCT05824871 (Sudapyridine (WX-081) in Rr/mdr/xdr-tuberculosis Patients).

Mechanism: Pharmacologically active on ATP synthase subunit c
Curator reviewed
Formula / weight: C₃₄H₃₃ClN₂O₂ · 537.1 g/mol (avg)
Also known as: 3-Pyridineethanol, 5-(4-chlorophenyl)-α-[2-(dimethylamino)ethyl]-2-methoxy-α-1-naphthalenyl-β-phenyl-, (αS,βR)- · αS,βR)-5-(4-Chlorophenyl)-α-[2-(dimethylamino)ethyl]-2-methoxy-α-1-naphthalenyl-β-phenyl-3-pyridineethanol
Code names: WX-081

Resolves to

Compound

Structure

InChIKeyMMUCHWPQRGEHDV-ZFEZZJPFSA-NSMILESCOC1=NC=C(C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=CC=CC=C12)C1=CC=C(Cl)C=C1

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sudapyridine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.